Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone.
Effect of testosterone treatment on the trabecular bone score in older men with low serum testosterone.
复制标题
DOI:
10.1007/s00198-021-06022-1
复制
发表时间:
2021-11
期刊:
影响因子:
--
通讯作者:
Snyder PJ
中科院分区:
文献类型:
--
作者:
Cauley JA;Ellenberg SS;Schwartz AV;Ensrud KE;Keaveny TM;Snyder PJ
In the Bone Trial of the Testosterone Trials, testosterone treatment increased trabecular volumetric bone mineral density (vBMD) and increased estimated bone strength as determined by finite element analysis. The Trabecular Bone score (TBS) is an indirect measure of vertebral bone microarchitecture. TBS predicts fracture independent of lumbar spine areal (a)BMD. The objective of this study was to examine the effect of testosterone treatment on TBS compared to its effects on vBMD and aBMD. 211 men were enrolled in the Bone Trial of the Testosterone Trials. Of these, 197 men had 2 repeat TBS and vBMD measurements; 105 men were allocated to receive testosterone and 92 men to placebo for one year. TBS, aBMD and vBMD were assessed at baseline and month 12. There was no difference in the percent change in TBS by randomized group: 1.6% (95% Confidence intervals (CI) 0.2–3.9) in the testosterone group and 1.4% (95% CI −0.2, 3.1) in the placebo group. In contrast, vBMD increased by 6% (95% CI 4.5–7.5) in the testosterone group compared to 0.4% (95% CI −1.65–0.88) in the placebo groups. TBS is not clinically useful in monitoring the one-year effect of testosterone treatment on bone structure in older hypogonadal men. The Trabecular Bone score (TBS) is an indirect measure of vertebral bone microarchitecture. Our objective was to examine the effect of testosterone treatment on TBS. 197 hypogonadal men were randomized to testosterone or placebo. After 12 months, there was no difference in the changes in TBS by randomized group.
登录
查看更多内容
DOI:
10.1007/s00198-017-4304-9
发表时间:
2018-03
期刊:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
影响因子:
--
作者:
Bilezikian JP;Hattersley G;Fitzpatrick LA;Harris AG;Shevroja E;Banks K;Leder BZ;Zanchetta JR;Hans D
通讯作者:
Hans D
影响因子:
6.2
作者:
Popp, Albrecht W.;Guler, Sabina;Lippuner, Kurt
通讯作者:
Lippuner, Kurt
影响因子:
4.1
作者:
Di Gregorio, S.;Del Rio, L.;Winzenrieth, R.
通讯作者:
Winzenrieth, R.
影响因子:
4.1
作者:
Pothuaud, Laurent;Carceller, Pascal;Hans, Didier
通讯作者:
Hans, Didier
影响因子:
9.8
作者:
Morley, JE;Kaiser, FE;Garry, PJ
通讯作者:
Garry, PJ